CLINICAL_TRIALS
trial_result
· 2018-12-07
Clinical Trial Update: Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) [Phase 2]
Summary
Phase 2 study evaluating XmAb5871 for IgG4-related disease has completed, with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Xencor, Inc. | Conditions: IgG4-RD | Phase 2 | Status: COMPLETED | Results posted: 2018-12-07